AstraZeneca announced that it has received Swedish Medical Products Agency (MPA) approval for use of Nexium(R) (esomeprazole) in children aged 1-11 years with gastroesophageal reflux disease (GERD) in the reference member state of Sweden, with other European Union nations expected to follow.1 Nexium® will become the first of the proton pump inhibitors (PPI) currently available for the treatment of pediatric GERD to have a specific formulation developed for children. [click link for full article]

More: continued here

This entry was posted on Sunday, December 2nd, 2007 at 2:12 am and is filed under Acid Reflux/GERD. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.